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Table 1. Important Substances Produced by or Acting Through Vascular Endothelium 
Vasodilator 
Produced by endothelium 
Adenosine 
EDRF 
EDHF 
Peptidoleukotrienes 
PC% 
EE, 
W, 
=I2 
Acts through endothelium 
Acetylcholine 
ADP 
Bradykinin 
Catecholamines 
Histamine 
Peptidoleukotrienes 
Serotcnin 
Vasoconstrictor 
? Endothelin 
Peptidoleukolrienes 
Angiotensin 
Vasopressin 
Anticoagulant/ 
Antithromboticl 
Antiplatelet 
Adenosine 
EDRF 
Glycosaminoglycans 
Plasminogen activator 
FGE,, PGE, 
PW 
Thrombomodulin 
Tissue factor 
Heparin 
Procoagulant 
Collagen 
FVIII-VWF complex 
Fibronectin 
Plasminogen inhibitors 
ADP = adenosine diphosphate: EDHF = endotheliumderived hyperpolarizing factor; EDRF = endotheliun- 
derived relaxing factor: FVlll = coagulation factor VIII: PG = prostaglandin; VWF = von Willebrand factor. 
rapid arterial smooth muscle relaxation and increased blood and adenine nucleotides are attenuated when en 
flow. tional integrity iscompromised (5)(Fig. 3). 
Endotheliti modulation f 
Vascular endothelium also modulates vascular tone by activat- 
ing vasoconstrictors, such as angiotensin I, and inactivating 
vasodilators, such as bradykinin (1). Simultaneously, endothe- 
lium regulates the actions of vasoconstrictor substances, such 
as catecholamines, s rotonin, arginine and vasopressin, and 
the smooth muscle constriction in response to these stimuli s 
enhanced inthe absence of intact endothelium (Fig. 2). The 
vasorelaxant effects of agents such as histamine, l ukotrienes 
Recent evidence (67) indicates that endotheliu 
releases other vas ubstances, endothelin and an 
endothe~i~m-delve o~~~i~~ factor, which act to 
constrict and hyperpolarize vascular smooth muscle, respec- 
tively. In health, endothelium-derived substances allow 
blood vessels to undergo rapid adaptation to changes in 
both the concentration f vasoactive mediators and in he- 
modynamic conditions uch as blood flow (8) and shear 
stress (9). 
IY/H’D[;I;>=z 
1. Conversion of arachidonic a id into biologi- 
tally active substances. The first step in each pathway is
the incorporation f molccula~ oxygen into arachidonic 
acrd to form a hydroperoxide ntermediate (Shydroper- 
oxyeicosatetraenoic acid[%HPETE], 1 I-HPETE, 12- 
5-HETE ti4 
I 
4 
LTE4 
1 vtiii-tily-fyy I,- I, HETE 
HPETE or IS-HPETE). These hydroperoxides can 
spontaneously degrade to the corresponding 5- 
hydroxyeicosatetraenoic acid (SHETE) or are con- 
verted enzymatically to leukotrienes (LT), prostaglan- 
dins (PG), thromboxane (TX) or prostacyclin (PGI& 
The cyclooxygenase form prostaglandin G2 (PGG,) (by 
means of the intermediate I l-HPETE), an endoperox- 
ide, is the common precursor to the prostaglandins 
TXA2 PGEz 
I 
PGD2 PGI 
/ 
I 
PGFza 
TX82 6-kelo PGF1 Q 
I-keto PGEl 
thromboxane A2 (TXAJ and prostacyclin. The 5- 
lipoxygenase form leukotriene A4 (LTA,) is rapidly 
converted to leukotrienes B.,(ET&,,) ad C, (LTC4), and 
removal ofthe terminal mino acids in glutathione forms 
leukotrienes D4(LTD,) and E, (LTE,). HHT = hepta- 
decatrienoic a id; MDA = malondialdehyde. 
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Agm 2. hceeased contractile response of iat aortic 
rings without endot 
those of aortic rings 
to epi no~e~~~e~~~i~e and 5-bydroxyt~y~. 
tamine cetylcholine (A~bj-i~dMs 
in ring othelium is not seen in t 
endothelium. 
at e~dotheliu~-generate latelet stimuli such 
as collagen, fibronectin and thrombos 
toward and deposited in ttre basal lamin 
the lumen, thus avoiding coatdct with 
lumen. Studies by 
aggregation of platelets be- 
urthermore. direct a sion of platelets to endothelial cells 
even when endothelial cells are 
’ ’ . . ’ ’ ’ 0.25 1 * ’ 
Figure 3. Vasorelaxant effects of adenosine diphos- 0’ a 0 &j 7 6 5 4 8 (-IO!& 0 9 8 I 6 6 (-logeM) 
pi&e (ADP). leukotriene D4 (LTD,) and histamine in 
- . 
ADP 
precontracted aortic rings wrh endothelium (Endo 0) 
are not observed in aortic rings without endothelium 
(Endo 0). Other abbreviations as in Figure 2. 
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NO. 01 platelettl added fpef ml) 
Fip~ 4. Divergent contractile and rehXahlt efkts of piatelets on 
aortic nugs without (Endo 0) and with (Endo 0) endothelium. 
respectively. These ffects ofplatelets are concentration dependent. 
treated with aspirin, direct adhesion of platelets to endothe- 
lial cells rarely occurs in vivo, even when endothelial cells 
are damaged. Platelets do. however, adhere to subendo- 
thelial layers when the endothelial lining is damaged or 
interrupted. 
Platelet modulation ofeadothelial and smooth muscle func- 
tion, Activated platelets secrete a number of substances 
that modulate endotheliaf cell morphology and function. For 
example, circulating platelets are essential for the mainte- 
nance of endothelial lining. Capillaries of thrombocytopenic 
animals show thinning of the endothelial lining and develop 
ment of fenestrations that cause an increase in vascular 
permeability (14). It has been suggested that platelets release 
a growth factor that is necessary for appropriate endothelial 
cell proliferation and function. This peptide, which is neces- 
sary for maintenance of endothelial integrity, differs from 
platelet-derived growth factor. 
Activated platelets actually cause relaxation of blood 
vessels with intact endothelium, which appears to occur (IS Q 
result of release of endothelium-derived relaxing factor (Fig. 
4) (5). This vasorelaxant effect of platelets is not attenuated 
by cyclooxygenase inhibitors, which suggests that pros- 
taglandins are probably not involved in this platelet- 
mediated smooth muscle relaxation. Pharmacologic inter- 
ventions that enhance the hydrolysis of adenine nucleotides 
produced by aggregating platelets diminish vascular smooth 
muscle relaxation, suggesting that the release of adenine 
nucleotides from activated platelets causes expression of 
endothelium-derived relaxing factor (5). In support of the 
important role of endothelium in vascular smooth muscle 
response to aggregating platelets are studies (15-17) in 
isolated canine, rat and, more recently, human coronary 
artery rings that demonstrate smooth muscle contraction in 
response to aggregating platelets in the absence of endothe- 
hum (Fig. 4). These vasoconstrictor effects of aggregating 
Platelets appear to be mediated through the release of 
thromboxane A, and serotonin (15). 
t is noteworthy that platelet- 
derived growth factor is a potent vasoco strictor (18) and an 
important stimulus for prostacyclin release (I in, 
derived from activated platelets, amplifies Of 
platelet-derived growth factor on prostacyclin release (201, 
whereas beta-thromboglobulin, also released by activated 
platelets, inhibits prostacyclin production (211. Platelet- 
released factor 4 binds to heparan sulfate on the en 
released factor 4 would be expec to enhance the rate of 
thrombin formation. Importantly, many of the platelet- 
derived substances also stimulate release of ~onprosta~~a~- 
din-related endoihelium-derived re!axing %W:. This effect 
suggests that vasorelaxation in response to platelet activa- 
tion can be maintained in the absence of prostacyclin syn- 
thesis, as may be the case during ad inistration of aspirin or 
other cyclooxygenase inhibitors. latelet-derived growth 
factor, released by platelets as w as other cell lines, is 
important in the mainten ce of endothelial barrier (22). 
contribution of arack lib. These are 
produced in the platelets mm and are ~rn~o~aot 
in regulating vascular tone. Whereas vascular endot~el~~m 
predominantly produces prostacyclin, aggregating platelets 
form the vasoconstrictor thromboxane Az (Fig. I) (23). The 
substrate for thromboxane A2 formation, prostaglandin 
can be utilized for the fo . n of prostacyclin in the 
endothelium (24), but the en -derived prostaglandi~ 
I-I2 cannot be utilized by platelets to form thromboxane A,. 
These observations suggest that the transfer of endoperox- 
ides is unidirectional and, in normal states, favors vasore- 
laxation and platelet disaggregation over vasoconstriction 
and platelet aggregation in vivo. 
Leukocyte-Blood Vessel Interactions 
The role of leukocytes in vasomotion relates to the 
release of potent vasoactive and endothelium-damaging sub- 
stances. such as oxygen free radicals, leukotrienes, hydroxy 
f&ty acids, platelet-activating factor and proteases, as well 
as to the release of vasoprotective species such as prostacy- 
clin. nonp:ostaglandin vasorelaxants and fibrinolytic stimuli 
(25). 
Leukocyte migration and adhesion. In states of health, 
leukocytes tend to circulate freely in the intravascular space. 
In inflammation, however, leukocytes marginate locally 
along the vessel wall, adhere to the endothelial cells, migrate 
through interendothelial cell junctions and accumulate in the 
subcellular regions. It has been suggested that migration of 
leukocytes occurs by a change i net surface charge of 
leukocytes and endothelial cells, by ~~d~~i~~ the forces 
of repulsion (26!. Chemotactic factors such as complement 
fragments and leukotriene B, also promote leukocyte adhe- 
sion, as doe: platelet-activating factor released from a vari- 
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catalase. 
Free oxygen radicals, which promote b 
also highly toxic to endothelium, mitochon 
and can cause severe tissue injury (25). E 
processes also lead to destruction of labile amino acids, 
teine and Iysine. Oxygen free radicals can also 
by xantbine oxidase, mitochondria and cate- 
cholamine oxidation during myocardial ischemia (25). 
Superoxide radicals caase vascular smooth masck con- 
traction and enhancement of smooth mascle sensitivity to 
alpha-adrenergic agonists and other vasoconstrictors in rat 
aortic segments (32). In addition, e~dotbelium-dependent 
smooth muscle relaxation is attenuated in the presence of 
s, most likely as a result of the inactiva- 
m-derived relaxing factor (33). Scanning 
y of arterial segments exposed to super- 
oxide radicals shows extensive disruption of en 
cells with cell thinning, vacuolization and lifting off of the 
basal lamina. These adverse effects of superoxide radicals 
can be abolished by the presence of the superoxide radical 
ecrease coronary bloo 
undergoes mild contraction, whereas modest relaxation oc- 
curs in response to higher concentrations ( IO6 to IO’ cells/ 
ml). In contrast, neutrophils cause potent concentration- 
dependent smooth muscle relaxation in dee~dotheIiaIi~ed 
vascular rings. These vasorelaxant esfects of neutrophils are 
potentiated by agents that scavenge or limit the production 
of superoxide radicals, such as captopril and superoxide 
dismutase (41.42). Such effects of unstimulated neutrophils 
are inhibited by agents known to compete with soluble 
guanylate cyclase, uch as methylene blue 
but are unaffecte by cyclooxyge~ase i 
observations suggest that u~stimulated ne 
a substance with biologic activity identical or s 
of eudothelium-derived relaxing factor (41). In 
~eutro~hils have recently been shown 
oxide when incubated in buffer at 37°C with 
of any stimulus (43). In addition, the smooth 
effects of neutrophils are more pronounced i 
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jzed vascular segments (41). These observations indicate 
that vascular endothelium ay act as a protective barrier 
against the full vasorela, it effects of neutrophils. This may 
have relevance in conditions uch as septic shock, when 
endotoxins may destroy the endothelium and high circulat- 
ing concentrations f neutrophils may cause intense vasore- 
laxation unopposed bythe endothelial barrier. Furthermore, 
in conditions such as coronary angioplasty, circulating neu- 
trophils may cause vasorelaxation and oppose the vasocon- 
strictor effects of other cells in circulation, such as platelets. 
Neutrophihderived relaxing factor. Preliminary observa- 
tions from our laboratory indicate that suspension f calcium 
ionophore A23187-stimulated neutrophils in an organ bath 
containing rat aortic rings with intact endothelium causes 
modest contraction followed by intense vasorelaxation. It is 
quite likely that the release of superoxide radicals from 
stimulated neutrophils causes arterial endothelial njury, and 
the neutrophil-derived r laxing factor then induces intense 
smooth muscle relaxation. The observation that both the 
initial contraction ofvessels and the subsequent vasorelax- 
ation are attenuated in the presence ofsuperoxide ismutase 
supports this hypothesis. Although stimulated neutrophils 
generate 20 to 40 ng/107 cells of leukotriene Bq, lipoxygenase 
inhibitors do not modulate the effects of neutrophil-derived 
relaxing factor. It is noteworthy that leukocyte-derived 
proteolytic enzymes along with leukotriene B4 and free 
oxygen radicals enhance vascular permeability and cause 
tissue edema (25). Lastly, leukocytes, pecifically mono- 
cytes, are another source of a variety of growth factors. 
Leukocyte-Platelet Interactions 
Inhibition and potentiation f platelet aggregation. I ter- 
actions between leukocytes and platelets serve to amplify 
and modulate he actions of each other. Unstimulated neu- 
trophils (also lymphocytes) inhibit adenosine diphosphate 
(ADP)-stimulated platelet aggregation a d probably help 
maintain platelet homeostasis. The factor that causes plate- 
let inhibition may be the same as neutrophil-derived r laxing 
factor. Elastase, a proteolytic enzyme released from neutro- 
phils, may also be responsible for inhibition of platelet 
aggregation because it has been shown to reduce the number 
of thrombin-binding sites and mediate proteolysis ofglyco. 
protein Ib (44). Oxidized hemoglobin and methylene blue 
reduce and superoxide ismutase potentiates the neutrophil- 
induced platelet aggregation inhibition. 
Several other leukocyte-derived products, including hy. 
drogen peroxide, superoxide radicals and peptidoleuko- 
trienes, Potentiate platelet aggregation (45,461. Alterna- 
tively, Products of platelet activation, such as serotonin, 
epinephrine, ADP, ATP and platelet-derived growth factor, 
enhance neutrophil adhesion (47). The presence ofplatelets 
stimulates neutrophil leukotriene B, production, chemotaxis 
(48) and superoxide radical generation (49). It appears that 
the platelet-derived 12.lipoxygenase metabolite 12- 
hydroperoxyeicosatetraenoic acid (Fig. I) stimulates t 
enzyme 5-lipoxygenase in neutrophils and enhances t 
production of both S-hydroxyeicosatetraenoic acid and leu- 
kotriene B,, (50) and, hence, neutrophil activity. 
mediated stimulation of human neutrophil functio 
modulated by cyclooxygenase inhibitors (48). However, 
neutrophils have been shown to utilize platelet-derived en-
doperoxides to synthesize prostacyclin (51), which may be a 
mechanism tocounteract the effects 
tory substances during i~t~avascMlar t 
Thus, the normal physiologic sta 
complex interactions between circulating cellular elements 
and vascular endothelium. Endothelial cells, platelets and 
leukocytes ach produce both vasoconstrictor and vasodila- 
tor substances and may thus act together to promote or 
inhibit thrombosis. In healthy settings, these interactions 
serve to maintain vascular tone and integrity during physio- 
logic perturbations (Fig. 5). As will be discussed, the patho- 
physiology of ischemic heart disease may be better under. 
stood through the characterization f alterations in the 
function of any or all of these cellular elements. 
Atherosclerosis 
In its initial form, the “response to injury hypothesis” 
(52) theorized that hemodynamic stress injures the arterial 
channel, causing adisruption of the endothelial lining and 
exposure of subendothelium on which platelets adhere, 
become activated and lead to intimal smooth muscle prolif- 
eration. More recent investigations have identified a pre- 
dominant role for leukocytes, principally monocytes, inthe 
initiation of fatty streak. Studies (53.54) in hypercholester- 
olemic nonhuman primates revealed clustering and adher- 
ence of monocytes tovascular endothelium within 12 days of 
diet-induced hypercholesterolemia. These fatty streaks con- 
tinue to grow by means of additional c ustering and suben- 
dothelial migration ofmonocytes, accumulation f lipids and 
finally proliferation of smooth muscle cells that have mi- 
grated to the vascular intima (52). 
Role of cholesterol. The relation between hypercholeste- 
rolemic diet and the appearance of monocytes on vascular 
endothelium ay relate to the ability of cholesterol and other 
lipid constituents of atheroma to activate complement and 
thereby stimulate l ukocytes. It has been reported (55,56) 
that cholesteml activated complement and yielded a small 
chemotactic fragment of Cs, thought o be C,, or C,, 
(desarginine). Activated complement-rich plasma is a pow- 
erful stimulus for neutrophil aggregation a d may mediate 
stimulation of monocytes and their adherence tothe endo- 
thelium directly by means of chemoattractants or neutrophil- 
vasoconslmon 
giggle 5. Interactions among e~dotbe~~Mrn, ytes and plate- 
lets. Platelet-derived products exert multiple s on leukocytes 
and blood vessels. For example, thromboxa~e A, WA,) and 
5-hydroxytryptamine (MIT) cause stri&on aid 12. 
~ydro~eroxyeicosa~e~rae~oic acid (12- 
cyte activities; adenosine dip~ospba 
tryptamine also cause smooth muscle (S 
of endothelium-derived relaxing factor (EDRF) release. Leukocytes 
also exert multiple influences on ceiLcell interactions: ~eptidole~- 
kotrienes (LTs) stimulate platelets and induce smooth muscle con- 
striction, but can also release ndothelium-delved r laxing factor 
and induce vasodilation, w”lereas platelet activating factor IPAF) 
causes platelet aggregation. ~eutro~hi~-generated superoxide radi- 
cal (02-) degrades endothelium-derived relaxing factor. Endothe- 
lium (ENDO)-generated r laxing factor and prostaglandin Iz WXJ 
exert inhibitory effects on platelets and leukocytes and relax vascu- 
lar smooth muscle. Endothelin constricts vascular smooth muscle. 
Adv = adventitia; B = basement membrane. 
monocyte interactions. Platelets rich in cholesterol also are 
hyperaggregable in response to a variety of stimuli and 
synthesize large amounts of thromboxane A2 (57). Recent 
studies from our laboratory (58) indicate increased chemo- 
tactic response of neutrophils from hypercholesterolemic 
patients compared with that in subjects with normal plasma 
cholesterol levels. However, the potential to generate super- 
oxide radicals and leukotriene is not altered. In additio 
generation of neutrophil-deriv nitric oxide is increase 
~ndothelinm from by~ercholesterolemic blood vessels, 
however, produces less endothelium-derived relaxing factor 
than does endot~elium from control vessels (59). 
The induction of endothelial adhesion glycoprotein (Gt’ 
150) by neutrophils mentioned previously may be a key 
mechanism in the clustering of leukocytes noted within the 
fatty streaks that appear early in atherogenesis. Leukocyte 
ression ofa~berosc~~~~sis. ~bQbania 
vasocons~ric~o~ m 
ctors, reseating in acc~mo~ation 
tinues to be the stimulus for growth and intimal migration of
vascular smooth muscle cells. These mitogenic factors also 
possess potent chemotactic properties that allow C~rther 
amplification f cell-cell interactions (47). 
It is obvious that atherosclerosis evolves over decades 
and its developmen? is influenced by hemodynamic stress, 
abnormal rheology and cell-eel! interactions. Endothelial 
injury and vascular response to circulating blood elements, 
principally leukocytes and platelets, may determine the 
extent of blood flow in arterial channels exposed to hemo- 
tress. The presence of 
a defect (or defects) in I 
cause important abnormalities in c 
factors collectively may lead to atherosclerosis and its 
clinical manifestations. 
s. It is evident that under cer- 
tain circumstances, reductions in hemodynamic stress (for 
example, hypertension) and byperlipidemic states may lead 
to a decrease in atherosclerosis and its complications in 
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humans (61.62). Although animal studies (63) have shown a 
decrease inatherosclerosis with platelet inhibitors uch as 
aspirin and sulfinpyrazone, supportive human studies are 
lacking. 
Stable Angina Pectoris 
Alterations in the function of vascular endothelium 
platelets and neutrophils have been observed among pa- 
tients with stable angina pectoris. Most patients with stable 
angina pectoris have coronary atherosclerosis. Atheroscle- 
rotic coronary artery segments from humans have been 
shown to have decreased relaxation responses toacetylcho- 
line and ether endothelium-derived relaxing factor-mediated 
vasodilators (59). In addition, the coronary artery smooth 
m:lscle response tovasoconstrictors is enhanced. In patients 
undergoing angiography, coronary blood flow has been 
shown to decrease markedly in response toacetylcholine in 
patients with coronary atherosclerosis and vasospasm, but 
not in subjects with normal coronary arteries (64,65). This 
finding clearly implies attenuation of endothelium-derived 
relaxing factor elease as a basis of reduced coronary flow 
reserve in atherosclerosis. Although earlier investigations 
suggested that prostacyclin release may be decreased in
atherosclerosis, recent observations (66) do not suggest a
reduction i prostacyclin generation i  atherosclerotic arter- 
ies from cholesterol-fed rabbits. 
Platelets in coronary artery dlseaw Hypercholesterol- 
emia has been associa:ed with coronary heart disease, and 
platelets rich in cholesterol produce large amounts of throm- 
boxane AZ (57). Studies of platelet function in patients with 
stable angina, however, have yielded mixed data. Overall, 
current evidence (67) suggests shortened platelet survival, 
intracoronary platelet consumption and perhaps platelet 
activation during stress. 
Neutrophil activity in angina pectoris, Recent studies (68) 
have demonstrated alterations in leukocyte function in pa- 
tients with stable angina pectoris. These include increased 
neutrophil chemotactic a tivity and enhanced potential to 
generate l ukotriene B4 (68). The enhanced neutrophil activ- 
ity in stable angina pectoris may have an important role in 
the progression f coronary artery disease. Increased activ- 
ity of neutrophils may result in in vivo platelet activation and 
subsequent thrombosis in atherosclerotic arteries. 
Unstable Angina PectorislAclcte Myocardial 
kfarction (Acute Myocardial schemia) 
The role of thrombosis n the pathogenesis of acute 
myocardial ischemia snow well established (69-71). Patho- 
logic studies (70) have demonstrated xtensive coronary 
atherosclerosis, plaque rupture, in vivo platelet activation 
and occlusive coronary thrombi in patients with acute myo- 
cardial ischemia. Elevated levels of thromboxa~e A2 
olites have been observed in coronary venous bl 
patients with unstable angina pectoris (72). and the platelets 
of patients with unstable angina pectoris are very sensitive to 
epinephrine and the thromboxarte 
Vasospasm and decrease 
stimuli. As discussed earli sclerotic artenes MSU- 
ally have decreased respocsiveness to vasodilator stimuli 
such as acetylcholine, ADP and histamine. Inthese arteries, 
responsiveness to ~eMro~umoral substances and platelet- 
and leukocyte-derived substances such as t~romboxa~e AZ,
serotonin and peptidoleukotrienes may be expected to be 
increased secondary to loss or diminution of e~dothe~i~ 
derived relaxing factor (Fig. 2 to 4). Platelet adhesion to the 
vascular subendothelium and subsequent activation may 
cause severe vasoconstriction (Fig. 4). Furthermore, syner- 
gistic effects of thromboxane A2and leukotrienes may cause 
a severe reduction in blood flow in narrowed coronary 
arteries (36). Increased circulating levels of catecholamines 
may serve to amplify vasoconstrictor responses toaggregat- 
ing telets. resulting in vasospasm. 
e of leukocytes in acute isehemia. More recent obser- 
vations have focused on the role of leukocytes in acute 
myocardial ischemia. High peripheral blood leukocyte 
counts are usually associated with acute myocardial lithe- 
mia, recurrent ischemic events after acute myocardial nfarc- 
tion and ventricular rrhythmias. Some recent studies (68) 
indicate generalized neutrophil activation i  acute myocar- 
dial ischemia, evidenced by spontaneous clumping of neu- 
trophils with ragged margins, granular extension and the 
appearance of intercellular ttachment on electron micros- 
copy. Leukocyte lastase l vels in peripheral plasma re 
increased about U-fold in patients with unstable angina 
pectoris, implying in vivo activation of neutrophils. Al- 
though elastase is associated with inhibition of platelet 
aggregation, high elastase l vels along with supcroxide rad- 
icals and leukotriene B, may participate in increased coro- 
nary vascular permeability, resulting in neutrophil accumu- 
lation and edema in ischemic myocardial tissues (25). 
Myocardial neutrophil accumulation a d edema long with 
loss of endothelial relaxation may result in compression f 
the microvasculature in ischemic tissue. 
Consequences of neutrophil accumulation and subse- 
quent activation are sign$cant and have been addressed in 
several animal studies (68J.5). Accumulation f neutrophils 
may relate to the loss of coronary vasodilator reserve 
(76-78). genesis of arrhythmias (79,80) and myocardial stun- 
ning during reperfusion (25.75). Although leukocytes are 
predominantly considered mediators ofresponses detrimen- 
tal to the host in these studies, they have also been shown to 
mediate plasmin-independent ~bri~~lysis ($1). In addition, 
they may scavenge dead tissue. Thus, leukocytes in acute 
myocardial ischemia may provide, in part, a defense against 
thrombosis and participate in tissue remodeling. 
s were treated with 
in leukocyte migration, or to both. Several studies are in 
progress to determine the benefit of superoxide radical 
scavengers in htrmans. 
The reocclusion that occurs after successful dilation of a 
previously narrowed coronary artery subjected to angio- 
plasty or surgical bypass grafting is a m 
limiting the efficacy of these procedures. 
that reocclusion develops in approximately 30% to 40% of 
patients after angioplasty (94) and approximately 10% to 
20% after bypass grafting within 6 to I2 months (95). 
ial injory. The ~atbo~hysioiogy of reoc- 
t a response to endothelial injury (52). 
Histologic evidence (96.97) in experimental animals showed 
that after damage to the vascular intima by angioplasty or 
bypass grafting, endothelium is denuded, with subsequent 
platelet adhesion and fibrin deposition. Studies (98) in non- 
human primates with endothelial destruction 
platelet activation followed by intimal smooth muscle prolif- 
eration 5 to 7 d;ys later. It seems likely that these changes 
are mediated by mitogens such as platelet-derived growth 
factor released secondary to tissue injury. In humans under- 
going these procedures, there is evidence (99) for release of 
essels to elicit 
t relaxation between arterial and venous coronary 
release of e~dotbe~ium~ 
I mammary artery com- 
usele responses to contrac- 
tile and relaxant stimuli may be resolved. However, recent 
ies of Va~boutte (102) indicated that despite regenera- 
of e~dotheli~m over 4 to 8 weeks after catheter-induced 
deendothelialization. vascular relaxation in response to ser- 
inues to be impaired. These data imply that 
ialization may not necessarily generate adequate 
ndothelium-derived relaxing factor. The obser- 
vations also suggest a continued tendency toward vasocon- 
striction and blood flow reduction in the early months after 
coronary artery bypass grafting and angioplasty. The first 4 
to 8 weeks after these procedures are well known for having 
the highest incidence of vessel reocclusion. 
Thm, in condirions qf rasculnr annslomosis and calhe- 
rer-induced irltirnnl irtjrc 
environment of enhance 
diminished e~dothe~ia~ inte 
anisms that ordinarily 
flow and prevent throm 
directed at increased v 
sequence, tissue perfusion may be impaired, resulting in 
vasospasm and localized thrombus formation. 
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The pharmacologic treatment of ischemic heart disease 
includes interventions that are meant to interfere directly 
with the cellular elements just discussed as well as others 
that although often administered for another desired effect, 
nonetheless participate in the modification of cellular fUnC- 
tion. The following is a brief discussion of the cellular effects 
of some commonly used pharmacologic agents as well as 
treatments for which information is just beginning to accu- 
mulate. 
Aspirin 
Cyclooxygenase inhibilion i platelets. As the important 
role of platelets in coronary thrombosis has become increas- 
ingly recognized, use of aspirin, a known inhibitor of platelet 
aggregation since the late 1960s. has become widespread in 
the primary and secondary prevention of unstable angina 
and myocardial infarction (103). Aspirin irreversibly inhibits 
cyclooxygenase (Fig. I), an enzyme responsible for the 
formation of the cyclic endoperoxkies prostaglandin G, and 
HZ. Depending on the particular type of cell in which 
cyclooxygenase exists, endoperoxides are converted to met- 
abolically active substances such as thromboxane A2 in 
platelets or prostacyclin in endothelium. Desired effects of 
cyclooxygenase inhibition include diminution of both throm- 
boxane AZ-mediated platelet aggregation and vasoconstric- 
tion. Obviously, inhlbition of vascular prostacyclin synthesis 
may be undesirable because this compound opposes platelet 
aggregation and causes vasodilation. Thus, recent work has 
focused on identifying an optimal dose of aspirin, one that 
consistently inhibits platelets, but has little or no effect on 
vascular cyclooxygenase. 
Dosage. It is noteworthy that both low and high doses of 
aspirin have proved equally beneficial in acute myocardial 
ischemia (103). This observation raises questions as to the 
relative importance of preservation of prostacyclin. None- 
theless, high doses of aspirin do cause gastrointestinal irri- 
tability and hemorrhage. Very lose dose regimens (I I .O 
mg/kg per day) yield adequate inhibition of platelet throm- 
boxane A2 production, have minimal effect on vascular 
prostacyclin synthesis (104) and are clinically effective in 
reducing the incidence of acute myocardial infarction or 
death in patients with unstable angina (105). Furthermore, 
the Physicians Health Study (106) demonstrated that taking 
small doses of aspirin (325 mg every other day) reduced the 
fmWnCY of cardiac events in asymptomatic healthy U.S. 
physicians, although a similar British study (107) utilizing 
higher doses of aspirin did not realize similar results. None- 
theless, both of these regimens have been shown to protect 
against restenosis of coronary bypass grafts (108,109) and to 
cause few side effects. 
Other actions of aspirin. 3espite pro~o~gi~~ bleeding 
time, aspirin does not totally inhibit platelet function. Ex- 
perimental studies have demonstrated that despite 
with aspirin, platelets can exhibit aggregatory res 
thrombin, ADP and collagen as well as displa 
interactions with each other, von Willebrand factor and 
fibrinogen. Additionally, it is important to note that although 
aspirin inhibits both platelet aggregation and release reac- 
tion, it exerts a multitude of other actions; for e it 
increases interleukin-2 and interferon production i O- 
cytes and decreases no ediated arrbythm~as, vas- 
cular growth and deen thelialization and stress-in 
release of t-PA by endothelial cells (I 10). 
Beta-Adrenergic Blocking Agents 
Beta-adrenergic blockers are used frequently in many 
forms of cardiovascular disease, including hypertension, 
angina pectoris, acute myocardial infarction and arrhyth- 
mias. Although their choice for cli;tical application is usually 
aimed at diminishing myocardial oxygen demand through 
negative chronotropic and inotropic effects, their effects on 
platelets and neutrophils may also be relevant with respect 
to their impact on ischemic heart disease. 
Effect on platelets. In general, beta-adrenergic blockers 
appear to inhibit platelet function. Propranolol has been 
shown to inhibit thromboxane AZ synthesis and platelet 
aggregation after Inng-term oral administration in humans 
(I I I, I 12). Further studies (113) have associated di 
platelet activity after treatment with metoprolol and propmn- 
0101 with changes in platelet cyclic AMP. Thus, the antiplste- 
let activity accompanying the use of beta-adrenergic block- 
ers be an additional beneficial effect of these agents. 
t on leukocyte function. Beta-adrenergi; blockers 
appear to enhance leukocyte function. Despite initial studies 
(114,115) demonstrating the importance of beta-adrenergic 
tone on leukocyte demargination and subsequent recruit- 
ment for participation in so-called stress reactions, recent 
studies (I 16) have identified that beta-blockers amplify neu- 
trophil adhesion. activation and microvascular injury. Simi- 
lar studies (117) demonstrate enhanced in vitro neutrophil 
spontaneous migration, chemotaxis, aggregation and in vivo 
inflammatory exudation in response to propranofol and 
alprenolol as well as enhanced spontaneous migration, 
chemokinesia and chemotaxis in response to d-propranolol, 
metoprolol and sotalol, but not acebutolol, pindolol. timolol 
or atenolol. Enhanced neutrophil activity may result in 
transient or permanent microvascular occlusion as well as 
activation of platelets and destruction of endothelium, with 
resultant loss of protective endothelial-derived products. 
Indeed, there are reports associating variant angina (118). 
migraine headache (I 19) and Raynaud’s phenomenon (120) 
with the administration of beta-adrenergic blockers. 
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vascular synthesis of 
correlated p~~sta~yc~~ 
tor effects of verapa 
d by Fiirster (140). Although unpro 
derived relaxing factor after coronary re~e~~sio~ n dogs 
pretreated with verapamil. Ho verapamil did not 
prevent deterioration of coron w reserve in dogs 
subjected totemporary coronary QC ion (78). 
Nitrates 
at high coRcefltrat~o~s, t 
iscovery of at least one compo- 
nent of endothelium-derived r laxing factor being nitric 
oxide (41, nitrates, which are converted in vivo into nitric 
oxide, appear to be a logical choice for the management of 
agents are in part due to a prostagla~d~a-mediated “breaking 
action on oe~tro~hi~ activation.” 
mboxane synthetase inhibitors allow 
tion of cyclic endoperoxides with their potent pl 
without affecting thromboxane A2or prostacyclin formatioa. 
In animal models (153), these agents reduce infarct size 
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(comparable with that of thromboxane synthetase inhibitors) 
and decrease neutrophil infiltration, probably by means of a 
reduction i  platelet activation. Thromboxane r ceptor an- 
tagonists also reduce cyclic flow variations in narrowed 
coronary arteries (154) and in a recent clinical trial (155) 
were shown to improve graft patency after bypass grafting 
(155). In vitro studies (17) demonstrate hat platelet- 
mediated constriction of deendothelialized arteries i  com- 
pletely abolished by very low concentrations of thrombox- 
ane receptor antagonists. 
Fish and Fish-Derived Products 
For many years, the potentially beneticial role of n-3 
polyunsaturated fatty acids has been recognized (156). Epi- 
demiologic studies (157,158) have demonstrated a low prev- 
alence of atherosclerosis and death from myocardial infarc- 
tion among Greenland Eskimos. These findings were 
associated with a diet rich in n-3 polyunsaturated fatty acids 
as a source of dietary fat. Fish and fish-derived products are 
rich in n-3 polyunsaturated fatty acids, which decrease 
platelet activity, leukocyte chemotaxis, free oxygen radical 
release and leukotriene B4 formation and have a variety of 
potentially beneficial effects on lipid metabolism (159). Stud- 
ies (160) in pigs show preservation of endothelium- 
dependent responses of coronary arteries inanimals fed cod 
liver oil. Epidemiologic studies (161) in the Dutch population 
also show a decrease in the risk of death from coronary heart 
disease in proportion to the increase in fish consumption. 
Also, a recent trial (162) utilizing dietary fish oil supplemen- 
tation demonstrated a significantly reduced incidence of 
early restenosis after angioplasty. Although n-3 polyunsatu- 
rated fatty acids exert a potent inhibitory effect on cell-cell 
interactions, conclusive data await completion oflarge scale 
clinical trials that will better define the therapeutic roles of 
fish and fish oil in ischemic heart disease. 
Conclusions 
The intricate interrelations of platelets, leukocytes and 
vascular endothelium present both challenges and therapeu- 
tic opportunities in the treatment ofischemic heart disease. 
Through modulation f cellular function with current as well 
as developing pharmacologic interventions, the clinician 
may be able to interfere inthe pathophysiologic mechanisms 
responsible for initiation and progression of disease while 
saucing cellular function of ~orne~§~~~ic or 
“Protective” value. Continuing research allowing a more 
complete characterization of cell-cell interactions will yield 
better understanding of the mechanisms of vascular disease 
and improved attempts atits therapy. 
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